Akt

Akt inhibitors target Akt, also called protein kinase B (PKB), a serine/threonine kinase in cell survival signaling. In 1995 the Akt proto-oncogene product was identified as a target of phosphatidylinositol 3-kinase (PI3K) activated by platelet-derived growth factor. Insulin and insulin-like growth factor 1 activate the kinase through phosphorylation at Thr308 and Ser473. The three isoforms, Akt1, Akt2 and Akt3, phosphorylate substrates that control metabolism, proliferation and apoptosis. The category includes the allosteric inhibitor MK-2206 2HCl, the catalytic-site inhibitor capivasertib and the alkylphospholipid perifosine. SC79, by contrast, promotes Akt phosphorylation and serves as an activator in pathway studies.

Items 101-125 of 158

  • Akt1&PKA-IN-2
    Cat. No.
    A25747

    Akt1&PKA-IN-2

    Akt1&PKA-IN-2 (Compound R-29) is a AKT1 and PKA inhibitor with selectivity for CDK2, with IC50 values of 0.007 and 0.01 μM, respectively. Akt1&PKA-IN-2 is applicable for cancer research.

    1 mg
    $130.00
    5 mg
    $290.00
    All 6 sizes
  • XL-418
    Cat. No.
    A25749

    XL-418

    XL-418 is a potent dual inhibitor of Akt and p70S6K, demonstrating IC50 values of 1 nM for Akt1 and 2 nM for p70S6K. This compound effectively inhibits the phosphorylation of ribosomal protein S6 and GSK3β, making it a valuable tool in cancer research. XL-418 is particularly relevant for studies involving prostate carcinoma and breast cancer, contributing to the understanding of signaling pathways in tumorigenesis.

    5 mg
    $180.00
    10 mg
    $295.00
    All 5 sizes
  • AKT-IN-23
    Cat. No.
    A25756

    AKT-IN-23

    AKT-IN-23 is a selective inhibitor of the AKT kinase, a crucial component in the PI3K/AKT signaling pathway. This compound effectively inhibits AKT activity, leading to decreased cell proliferation and survival in various cancer cell models. AKT-IN-23 is useful in cancer research, particularly in studies focused on the modulation of signaling pathways associated with tumor progression and therapeutic resistance.

    5 mg
    $195.00
    10 mg
    $325.00
    All 5 sizes
  • Hu7691 free base
    Cat. No.
    A25758

    Hu7691 free base

    Hu7691 free base is a selective inhibitor of AKT, demonstrating IC50 values of 4.0 nM, 97.5 nM, and 28 nM for AKT1, AKT2, and AKT3, respectively. This compound exhibits significant antitumor activity and has been shown to reduce cutaneous toxicity in murine models. Hu7691 free base is valuable in research focused on cancer therapeutics and the modulation of the AKT signaling pathway.

    1 mg
    $235.00
    5 mg
    $590.00
    All 5 sizes
  • AT7867 hydrochloride
    Cat. No.
    A25763

    AT7867 hydrochloride

    AT7867 hydrochloride is a potent inhibitor of AKT and p70 S6 kinase, exhibiting strong oral activity. This compound demonstrates significant anticancer properties, making it a valuable tool in cancer research. Its efficacy in targeting critical signaling pathways involved in cellular growth and survival supports its use in exploring therapeutic strategies for various malignancies.

    10 mg
    $330.00
    50 mg
    $1,380.00
    All 2 sizes
  • MK-2206 free base
    Cat. No.
    A25765

    MK-2206 free base

    MK-2206 free base is a highly potent and selective allosteric inhibitor of the Akt signaling pathway, exhibiting IC50 values of 8 nM, 12 nM, and 65 nM for Akt1, Akt2, and Akt3, respectively. This compound demonstrates significant anticancer properties, particularly against breast cancer cell lines, as well as those harboring PIK3CA mutations and PTEN loss. MK-2206 free base is valuable for research applications focused on cancer biology and therapeutic development targeting the Akt pathway.

    Out of stock

    All 3 sizes
  • AKT-IN-5
    Cat. No.
    A25769

    AKT-IN-5

    AKT-IN-5 is a selective inhibitor of Akt1 and Akt2, exhibiting IC50 values of 450 nM and 400 nM, respectively. This compound has been shown to effectively modulate the Akt signaling pathway, which plays a critical role in cell survival, proliferation, and metabolism. AKT-IN-5 is valuable for research applications focused on cancer biology, metabolic disorders, and other conditions driven by aberrant Akt activity.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • 22-(4′-py)-JA
    Cat. No.
    A25779

    22-(4′-py)-JA

    Synonyms: 22-(4′-Pyridinecarbonyl) jorunnamycin A

    22-(4′-py)-JA is a semisynthetic derivative of junamycin A, primarily targeting the AKT/mTOR/p70S6K signaling pathway. This compound exhibits significant antimetastatic activity by inhibiting tumor cell invasion and tube formation in human umbilical vein endothelial cells (HUVEC). Furthermore, 22-(4′-py)-JA downregulates key factors including metalloproteinases (MMP-2 and MMP-9), hypoxia-inducible factor 1α (HIF-1α), and vascular endothelial growth factor (VEGF). Its potent anticancer properties make it a valuable tool for research, particularly in non-small cell lung cancer (NSCLC) studies.

    Out of stock

    All 3 sizes
  • RLX
    Cat. No.
    A25782

    RLX

    Synonyms: PD 139530

    RLX (PD 139530) is a potent inhibitor of the PI3K/Akt/FoxO3a signaling pathway, exhibiting significant therapeutic potential in colon cancer models. This compound can effectively modulate the tumor microenvironment, thereby enhancing the efficacy of cancer immunotherapy. Additionally, RLX improves the retention time of therapeutic agents in tumors through advanced nanoparticle delivery systems and can be combined with various treatment modalities, such as chemotherapy and radiotherapy, to synergistically enhance cancer treatment outcomes.

    1 mg
    $235.00
    5 mg
    $590.00
    All 6 sizes
  • AKT-IN-14
    Cat. No.
    A25785

    AKT-IN-14

    AKT-IN-14 is a highly potent inhibitor of AKT, demonstrating IC50 values of less than 0.01 nM for AKT1, 1.06 nM for AKT2, and 0.66 nM for AKT3. This compound is primarily utilized in cancer research, providing valuable insights into AKT signaling pathways and therapeutic interventions. Its exceptional specificity and efficacy make it a crucial tool for investigating the role of AKT in tumorigenesis and cancer progression.

    Out of stock

    All 3 sizes
  • PI3K/AKT-IN-5
    Cat. No.
    A25786

    PI3K/AKT-IN-5

    PI3K/AKT-IN-5 is a selective inhibitor of the PI3K/AKT signaling pathway. It demonstrates potent anti-cancer activity, particularly in colorectal cancer models, by significantly inhibiting cell colony formation, inducing G2/M phase cell cycle arrest, and promoting apoptosis. This compound serves as a valuable tool for research into the mechanisms of colorectal cancer progression and treatment.

    Out of stock

    All 3 sizes
  • AKT1-IN-10
    Cat. No.
    A25793

    AKT1-IN-10

    AKT1-IN-10 is a non-covalent allosteric inhibitor of AKT1, exhibiting an IC50 of less than 500 μM. This compound demonstrates oral bioavailability, making it a viable candidate for in vivo studies. AKT1-IN-10 is primarily utilized in cancer research, providing insights into the modulation of AKT signaling pathways and their implications in tumor progression.

    Out of stock

    All 3 sizes
  • AKT-IN-8
    Cat. No.
    A25794

    AKT-IN-8

    AKT-IN-8 is a potent inhibitor of AKT, exhibiting IC50 values of 4.46 nM for AKT1, 2.44 nM for AKT2, and 9.47 nM for AKT3. This compound demonstrates significant inhibitory activity, making it a valuable tool for studying AKT signaling pathways. It is applicable in cancer research and investigations into the role of AKT in various cellular processes, including metabolism, proliferation, and survival.

    25 mg
    $1,800.00
    50 mg
    $2,285.00
    All 3 sizes
  • AKT-IN-10
    Cat. No.
    A25798

    AKT-IN-10

    AKT-IN-10 is a selective inhibitor of AKT (Protein Kinase B), a crucial component of the PI3K/AKT/mTOR signaling pathway that regulates cell growth, survival, differentiation, and metabolism. This compound demonstrates significant potential for applications in cancer research, particularly in breast and prostate cancer studies, by effectively modulating AKT activity. Its ability to interfere with AKT signaling positions AKT-IN-10 as a valuable tool for investigating therapeutic strategies targeting these malignancies.

    25 mg
    $1,800.00
    50 mg
    $2,285.00
    All 3 sizes
  • Alborixin
    Cat. No.
    A25800

    Alborixin

    Alborixin is a potent inhibitor of the PI3K-AKT signaling pathway that promotes autophagy. It facilitates the clearance of intracellular and extracellular amyloid-β by upregulating key autophagy-related proteins such as BECN1, ATG5, and ATG7, while enhancing lysosomal activity. This mechanism yields a reduction in amyloid-β-mediated neurotoxicity, positioning Alborixin as a valuable tool for research related to Alzheimer's disease and other neurodegenerative conditions.

    Out of stock

    All 3 sizes
  • APN/AKT-IN-1
    Cat. No.
    A25807

    APN/AKT-IN-1

    APN/AKT-IN-1 is a potent dual inhibitor targeting aminopeptidase N (APN) and protein kinase B (AKT), exhibiting IC50 values of 0.21 μM and 0.27 μM, respectively. This compound effectively blocks the phosphorylation of glycogen synthase kinase 3 beta (GSK3β), a critical substrate of AKT, thereby modulating key signaling pathways involved in cell growth, survival, and metabolism. APN/AKT-IN-1 is valuable for research applications focusing on cancer biology and therapeutic interventions targeting the APN/AKT pathway.

    Out of stock

    All 3 sizes
  • TCL1(10-24)
    Cat. No.
    A25809

    TCL1(10-24)

    TCL1(10-24) is a specific Akt inhibitor that targets the PH domain of Akt, disrupting its interaction with phosphoinositides. This inhibition prevents Akt's membrane translocation and subsequent activation, thereby hindering cellular proliferation and promoting apoptosis. TCL1(10-24) demonstrates significant antitumor activity in vivo, making it a valuable reagent for cancer research and studies focused on cell survival mechanisms.

    Out of stock

    All 3 sizes
  • Akt1-IN-3
    Cat. No.
    A25810

    Akt1-IN-3

    Akt1-IN-3 is a selective inhibitor of AKT1, demonstrating potent inhibition with an IC50 value of less than 15 nM against the AKT1-E17K mutant. This compound is valuable for research applications exploring the role of AKT signaling in various cancers and other diseases. Its potency and specificity make it an essential tool for studies aimed at understanding AKT1-related pathways and developing targeted therapies.

    25 mg
    $1,405.00
    50 mg
    $1,790.00
    All 3 sizes
  • Antiangiogenic agent 4
    Cat. No.
    A25819

    Antiangiogenic agent 4

    Antiangiogenic agent 4 is an Akt phosphorylation inhibitor that effectively disrupts the Akt signaling pathway in human foreskin fibroblast (HFF) and human umbilical vein endothelial cells (HUVEC). This compound demonstrates notable antiangiogenic activity, making it a valuable tool in cancer research aimed at understanding tumor growth and vascularization mechanisms.

    Out of stock

    All 3 sizes
  • PI3K/AKT-IN-2
    Cat. No.
    A25824

    PI3K/AKT-IN-2

    PI3K/AKT-IN-2 is a selective inhibitor of the phosphoinositide 3-kinase (PI3K) and AKT signaling pathways. This compound effectively prevents epithelial-mesenchymal transition (EMT) and promotes apoptosis in various cancer cell lines. Additionally, PI3K/AKT-IN-2 has been shown to inhibit tubulin polymerization, making it a valuable tool for research into cancer metastasis and cell proliferation.

    5 mg
    $160.00
    10 mg
    $265.00
    All 5 sizes
  • PDK1/Akt/Flt dual pathway inhibitor
    Cat. No.
    A25834

    PDK1/Akt/Flt dual pathway inhibitor

    PDK1/Akt/Flt dual pathway inhibitor selectively targets the PDK1/Akt/Flt signaling pathways, crucial for cell survival and proliferation. This compound demonstrates significant inhibitory activity, making it a valuable tool for research in cancer biology and therapeutic development. It can be utilized to explore the roles of these pathways in oncogenesis and to assess potential therapeutic strategies against malignancies driven by aberrant PDK1/Akt/Flt signaling.

    25 mg
    $1,275.00
    50 mg
    $1,625.00
    All 3 sizes
  • Akt1&PKA-IN-1
    Cat. No.
    A25839

    Akt1&PKA-IN-1

    Akt1&PKA-IN-1 is a potent dual inhibitor targeting both Akt and Protein Kinase A (PKA), exhibiting IC50 values of 0.03 μM for PKAα and 0.11 μM for Akt, with a higher IC50 of 9.8 μM for cyclin-dependent kinase 2 (CDK2). This compound demonstrates selective inhibition of CDK2, making it a valuable tool for research in cancer biology and cellular signaling pathways. Akt1&PKA-IN-1 is useful for studying the regulatory role of these kinases in cellular processes and potential therapeutic applications.

    1 mg
    $130.00
    5 mg
    $290.00
    All 6 sizes
  • IBL-302
    Cat. No.
    A25844

    IBL-302

    Synonyms: AMU302

    IBL-302 is an orally available dual inhibitor targeting PIM and the PI3K/AKT/mTOR pathways. It exhibits significant antitumor activity against breast cancer and neuroblastoma, showing in vivo efficacy in nude mouse xenograft models by overcoming trastuzumab resistance. Additionally, IBL-302 enhances the cytotoxic effects of commonly used chemotherapeutic agents, including cisplatin, doxorubicin, and etoposide, making it a valuable compound for cancer research applications.

    1 mg
    $310.00
    5 mg
    $805.00
    All 4 sizes
  • (R)-Capivasertib
    Cat. No.
    A25854

    (R)-Capivasertib

    Synonyms: (R)-AZD5363

    (R)-Capivasertib is the R-enantiomer of Capivasertib, a potent inhibitor of AKT1, AKT2, and AKT3, which are critical components of the PI3K/Akt signaling pathway. This compound exhibits significant antitumor activity by interrupting cancer cell proliferation and survival mechanisms. It is primarily utilized in research related to cancer biology, specifically for studying targeted therapies and resistance mechanisms in various malignancies.

    5 mg
    $140.00
    10 mg
    $225.00
    All 5 sizes
  • MKC-1
    Cat. No.
    A25858

    MKC-1

    Synonyms: Ro-31-7453

    MKC-1 is an orally active and potent inhibitor targeting the Akt/mTOR signaling pathway. This compound exhibits broad antitumor activity by arresting cellular mitosis and inducing apoptosis. MKC-1 interacts with various cellular proteins, including tubulin and members of the importin β family, making it valuable for research in cancer cell cycle regulation and therapeutic mechanisms.

    1 mg
    $40.00
    5 mg
    $105.00
    All 6 sizes

Items 101-125 of 158

Added to your cart

View Cart Checkout

    Loading...